202 related articles for article (PubMed ID: 35212154)
21. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract][Full Text] [Related]
22. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
Wang L; Li L; Zhou X; Zhang D
Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
[No Abstract] [Full Text] [Related]
24. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
25. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
26. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
Lin X; Yang X; Tan Y; Duan Q; He M
Invest New Drugs; 2022 Oct; 40(5):1160-1163. PubMed ID: 35608716
[TBL] [Abstract][Full Text] [Related]
27. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract][Full Text] [Related]
28. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
29. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
[TBL] [Abstract][Full Text] [Related]
30. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
31. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
[TBL] [Abstract][Full Text] [Related]
33. Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
Xie X; Chen X; Luo N; Qi Y; Li M; Feng X
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2165-2168. PubMed ID: 35426613
[TBL] [Abstract][Full Text] [Related]
34. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
35. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
36. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
37. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
38. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
Liu D; Xu X; Wen J; Zhang C; Fan M
Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
[TBL] [Abstract][Full Text] [Related]
39. Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
Wang L; Yao S; Teng L; Zhang W; Chen L
J Thorac Oncol; 2020 Mar; 15(3):e44-e46. PubMed ID: 32093861
[No Abstract] [Full Text] [Related]
40. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.
Zhao R; Guo L; Zhang B; Zhao J; Xiang C; Chen S; Shao J; Zhu L; Ye M; Han Y
J Pathol Clin Res; 2022 Nov; 8(6):538-549. PubMed ID: 35848751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
